Format

Send to

Choose Destination
J Med Chem. 2009 Nov 26;52(22):7069-80. doi: 10.1021/jm900969p.

Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement.

Author information

1
Department of Medicinal Chemistry, Probiodrug AG, Weinbergweg 22, 06120 Halle, Germany.

Abstract

The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of Abeta(3,11(pE)-40,42), as these Abeta-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of Abeta-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of Abeta(3,11(pE)-40,42) formation.

PMID:
19863057
DOI:
10.1021/jm900969p
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center